Cipla, one of India’s leading pharmaceutical companies, is delighted to announce the appointment of Mr. Subhanu Saxena as its Chief Executive Officer. Subhanu comes to Cipla with rich work experience of 25+ years, having worked with companies such as Citicorp, The Boston Consulting Group, and PepsiCo, across markets in Europe, North America, Africa and Asia. In his last assignment he led the Global Product Strategy and Commercialization functions at Novartis Pharma AG. In this role, Subhanu was a part of the Global Pharma Executive Committee (USD 30 bn sales), with responsibility for marketing, sales, global medical affairs and health economics.
Exports of the Indian pharmaceutical industry are expected to move up from Rs 90,000 crore in the previous financial year to breach the Rs 1 lakh crore mark in 2014-15, according to Dr P V Appaji, Director General of Pharmaceuticals Exports Promotion Council (Pharmexcil). He added that majority of the export revenues for the country are expected to come from formulations and the issues faced by the industry earlier are now under control.
Pfizer CEO change could signal strategic switch
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK), was tested at the NIH Clinical Center in Bethesda, Maryland. The interim results are reported online in advance of print in the New England Journal of Medicine.
The Government of India has extended the deadline to affix the barcodes on mono-cartons (ointment, eye/ear drops) by the pharma companies to April 2015. It may be noted that barcodes are expected to help in tracking and tracing the origin of drugs, which minimises the chance of genuine medicines being considered spurious, substandard or counterfeit.
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and Ranbaxy Laboratories Ltd ( Reuters: RANB. BO, Bloomberg: RBXY IN, NSE: RANBAXY, BSE: 500359) announced that they have received the order of the Competition Commission of India (“CCI”) dated December 5, 2014 ( “Order” ) by which CCI has approved the acquisition of Ranbaxy by Sun Pharma, subject to compliance with certain conditions. Sun Pharma and Ranbaxy had filed the notice with the CCI on 6th May 2014 and sought its approval with respect to the deal. Over the past few months, the CCI has sought information and detailed clarifications for the purposes of making its assessment.
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.The study appears Dec. 1 in Clinical Cancer Research.
Merck & Co Inc said on Monday it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion, giving the major drugmaker an entry into the market for drugs that target so-called superbugs. Merck and British rival AstraZeneca Plc have turned their attention to newer kinds of antibiotics that attack superbugs — strains of bacteria that are resistant to several types of antibiotics — after the 2013 threat report from the U.S. Centers for Disease Control (CDC) and Prevention.
New Delhi, Jan 01, 2015: Seeking "highest possible level of good health" through preventive and promotive care, the Centre today put the draft of the new National Health Policy in the public domain to receive suggestions from various stakeholders. The policy's objectives are to improve the people's health status through concerted policy action in all sectors and expand preventive, promotive, curative, palliative and rehabilitative services provided by the public health sector, according to the draft put up at the Health Ministry's website. It also aims at a "significant reduction" in out of pocket expenditure due to health care costs and lowering of proportion of households experiencing "catastrophic health expenditures and consequent impoverishment".
LONDON: In a massive breakthrough, scientists have created the first new antibiotic in more than three decades, Teixobactin, that can treat many common bacterial infections such as tuberculosis, septicemia and C Diff or clostridium difficile colitis. The discovery comes at a time when World Health Organization has sent out warnings that humanity is staring at a post-antibiotic era when common infections will no longer have a cure. The first antibiotic, Penicillin, was discovered by Alexander Fleming in 1928, and more than 100 compounds have been found since then, but no new class has been found since 1987.
The Ministry of Health and Family Welfare is organizing 31stMeeting of Ministers of Health of Countries of the WHO South-East Asia Region and 66th Session of the WHO Regional Committee for South-East Asia at New Delhi between 10-13thSeptember, 2013. The President of India, ShriPranab Mukherjee will inaugurate the International Meeting on 10 September, 2013 at 11.30 am at RashtrapatiBhavan Auditorium. Almost 300 guests likely to attend the inaugural ceremonyinclude Hon’ble Health Ministers of the countries of WHO, South East Asia Region heading their respective country delegations, Director General, WHO (headquartered in Geneva), WHO Secretariat officers and staff, UN agencies in India, Intergovernmental organizations such as ASEAN and SAARC, Donors and partners, NGOs and partners, High Commissioners/Ambassadors from the countries of South East Asia region as well as from the prominent donor countries, officials from Ministry of Health & Family Welfare/Director General of Health Services, Government of India, Press and media.
Alantus pharmaceuticals PVT Ltd is dedicated to all aspects of healthcare in providing safe, effective, affordable products to sustain and save lives. We are marketers and suppliers of pharmaceutical products and quality is the first priority at Alantus. Our client list includes government, non- government, private institutions and we aim to ensure atmost customer satisfaction by offering quality products at affordable rates.